Isla Pharmaceuticals: Funding, Investors & Team (Nov 2026)
Island (ASX: ILA) is a drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases. We have a lead asset – ISLA-101 - that was initially developed by our wholly-owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquitoes (or vector) borne diseases. Dengue fever is the very definition of an unmet medical need. While 390 million humans are infected each year, it is thought that around 30-50% of people with the disease do not present with symptoms, enabling the virus to spread within communities. Warming global climates are accelerating the presence of mosquito-borne viruses that can cause death to the US, Europe and Australia There is no specific pharmaceutical treatment and the one vaccine which exists is available to a highly restricted audience. Island has repurposed ISLA-101, an antiviral oral drug to treat mosquito-borne viruses (eg dengue fever / Zika) and intends to complete Phase II studies with a significantly de-risked clinical program.
Isla Pharmaceuticals has raised $2.4M across 1 funding round on record, the most recent an undisclosed round of $2.4M announced in Oct 2024.
That round is below the $8.9M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Isla Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Isla Pharmaceuticals Funding Rounds
Isla Pharmaceuticals Founders and Leadership Team
Contact details for the Isla Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Isla Pharmaceuticals Funding Compared to Other Biotechnology Startups
Isla Pharmaceuticals' latest round of $2.4M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Isla Pharmaceuticals in Biotechnology and San Juan
Companies Similar to Isla Pharmaceuticals
Aspire Biopharma is a biotechnology company specializing in nanotechnology-based drug formulation and the…
Orakl Oncology is dedicated to accelerating drug discovery in oncology using advanced biology and AI-powered…
Araceli Biosciences specializes in creating scientific instruments for discovering tissue- and cell-based…
VectorY utilizes a combination of antibodies and gene therapy to create effective and long-lasting treatments…
Switchpoint Bio is a biotechnology company that offers immune relevant drug treatments.
Nanopath Inc. is a company that specializes in molecular diagnostics and allows for fast, high-quality…
Frontier Bio is creating lab-grown human tissues as an ethical replacement for animal studies and is setting…
Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel…
It is our mission to open a new chapter in treating diseases and to deliver so called selectively expressed…
altM's goal is to create and produce scalable biomaterials that can assist major industries in decreasing…
The Company's corporate purpose is: I) the development of new high-value biotechnological solutions based on…
Venomics AI is a drug discovery platform using venom peptides for therapeutics.
Isla Pharmaceuticals Funding FAQs
What does Isla Pharmaceuticals do?
Island (ASX: ILA) is a drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases. We have a lead asset – ISLA-101 - that was initially developed by our wholly-owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquitoes (or vector) borne diseases. Dengue fever is the very definition of an unmet medical need. While 390 million humans are infected each year, it is thought that around 30-50% of people with the disease do not present with symptoms, enabling the virus to spread within communities. Warming global climates are accelerating the presence of mosquito-borne viruses that can cause death to the US, Europe and Australia There is no specific pharmaceutical treatment and the one vaccine which exists is available to a highly restricted audience. Island has repurposed ISLA-101, an antiviral oral drug to treat mosquito-borne viruses (eg dengue fever / Zika) and intends to complete Phase II studies with a significantly de-risked clinical program.
How much funding has Isla Pharmaceuticals raised?
Isla Pharmaceuticals has raised $2.4M across 1 round on record. The most recent is an undisclosed round of $2.4M announced in Oct 2024.
When did Isla Pharmaceuticals last raise funding?
Isla Pharmaceuticals' most recent funding round on record is an undisclosed round of $2.4M, announced in Oct 2024.
Who founded Isla Pharmaceuticals?
FundedIQ lists David Foster (Founder) at Isla Pharmaceuticals.
Where is Isla Pharmaceuticals headquartered?
Isla Pharmaceuticals is based in San Juan, Na - Puerto Rico, Puerto Rico.
How many employees does Isla Pharmaceuticals have?
Isla Pharmaceuticals is in the 1-10 employee band.
How does Isla Pharmaceuticals' funding compare to other Biotechnology startups?
Isla Pharmaceuticals' latest round of $2.4M is below the $8.9M median round size for Biotechnology companies on FundedIQ across 4,188 tracked companies over the last two years.
About FundedIQ's Isla Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Isla Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.